scholarly journals Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data

2017 ◽  
Vol 34 (02) ◽  
pp. 145-166 ◽  
Author(s):  
Susan Shamimi-Noori ◽  
Carin Gonsalves ◽  
Colette Shaw

AbstractMetastatic liver disease is a major cause of cancer-related morbidity and mortality. Surgical resection is considered the only curative treatment, yet only a minority is eligible. Patients who present with unresectable disease are treated with systemic agents and/or locoregional therapies. The latter include thermal ablation and catheter-based transarterial interventions. Thermal ablation is reserved for those with limited tumor burden. It is used to downstage the disease to enable curative surgical resection, as an adjunct to surgery, or in select patients it is potentially curative. Transarterial therapies are indicated in those with more diffuse disease. The goals of care are to palliate symptoms and prolong survival. The indications and supporting data for thermal ablation and transarterial interventions are reviewed, technical and tumor factors that need to be considered prior to intervention are outlined, and finally several cases are presented.

2020 ◽  
Vol 37 (05) ◽  
pp. 484-491
Author(s):  
Cathal O'Leary ◽  
Michael C. Soulen ◽  
Susan Shamimi-Noori

AbstractMetastatic liver disease is one of the major causes of cancer-related morbidity and mortality. Locoregional therapies offered by interventional oncologists alleviate cancer-related morbidity and in some cases improve survival. Locoregional therapies are often palliative in nature but occasionally can be used with curative intent. This review will discuss important factors to consider prior to palliative and curative intent treatment of metastatic liver disease with locoregional therapy. These factors include those specific to the tumor, liver function, liver reserve, differences between treatment modalities, and patient-specific considerations.


2001 ◽  
Vol 45 (2) ◽  
pp. 147
Author(s):  
Jeong Nam Heo ◽  
Hyun Chul Rhim ◽  
Yong Soo Kim ◽  
Byung Hee Koh ◽  
On Koo Cho ◽  
...  

2003 ◽  
Vol 1 (5) ◽  
pp. S84
Author(s):  
F.R. Garcia-Arroyo ◽  
J.M. Garcia-Bueno ◽  
M. Constenia ◽  
C. Vadell ◽  
P. Palacios ◽  
...  

2016 ◽  
Vol 22 (6) ◽  
pp. 495-500 ◽  
Author(s):  
Osman Melih Topcuoglu ◽  
Musturay Karcaaltincaba ◽  
Deniz Akata ◽  
Mustafa Nasuh Ozmen

2013 ◽  
Vol 53 (5) ◽  
pp. 702-706 ◽  
Author(s):  
Katharine L. Aitken ◽  
Diana M. Tait ◽  
Christopher M. Nutting ◽  
Komel Khabra ◽  
Maria A. Hawkins

2015 ◽  
Vol 1 (1) ◽  
pp. 11-13
Author(s):  
John D. Goodwin ◽  
◽  
Jason Schmidt ◽  
Parvez Mantry ◽  
◽  
...  

Radiology ◽  
1970 ◽  
Vol 95 (3) ◽  
pp. 696-698 ◽  
Author(s):  
Carl M. Mansfield ◽  
Corinne Farrell ◽  
Sucha O. Asbell

2019 ◽  
Vol 9 (1) ◽  
pp. 56 ◽  
Author(s):  
Michael Köhler ◽  
Fabian Harders ◽  
Fabian Lohöfer ◽  
Philipp M. Paprottka ◽  
Benedikt M. Schaarschmidt ◽  
...  

Purpose: To evaluate factors associated with survival following transarterial 90Y (yttrium) radioembolization (TARE) in patients with advanced intrahepatic cholangiocarcinoma (ICC). Methods: This retrospective multicenter study analyzed the outcome of three tertiary care cancer centers in patients with advanced ICC following resin microsphere TARE. Patients were included either after failed previous anticancer therapy, including relapse after surgical resection, or for having a minimum of 25% of total liver volume affected by ICC. Patients were stratified and response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at 3 months. Kaplan–Meier analysis was performed to analyze survival followed by cox regression to determine independent prognostic factors for survival. Results: 46 patients were included (19 male, 27 female), median age 62.5 years (range 29–88 years). A total of 65% of patients had undergone previous therapy, while 63% had a tumor volume > 25% of the entire liver volume. Median survival was 9.5 months (95% CI: 6.1–12.9 months). Due to loss in follow-up, n = 37 patients were included in the survival analysis. Cox regression revealed the extent of liver disease to one or both liver lobes being associated with survival, irrespective of tumor volume (p = 0.041). Patients with previous surgical resection of ICC had significantly decreased survival (3.9 vs. 12.8 months, p = 0.002). No case of radiation-induced liver disease was observed. Discussion: Survival after 90Y TARE in patients with advanced ICC primarily depends on disease extent. Only limited prognostic factors are associated with a general poor overall survival.


Sign in / Sign up

Export Citation Format

Share Document